Exosomes are natural carriers of exogenous siRNA to human cells in vitro.
Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV, Filatov MV. · 2013
Read Exosomes are natural carriers of exogenous siRNA to human cells in vitro. by Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV, Filatov MV. (2013) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc3895799.txt.
Introduction
Tatyana A. Shtam, Roman A. Kovalev, Elena Yu Varfolomeeva, Evgeny M. Makarov, Yury V. Kil, and Michael V. Filatov test exosomes as RNA carriers in Cell Communication and Signaling in 2013. Exosomes are tiny vesicles cells shed to send RNA to each other. Silencing RNA, siRNA, can switch off a chosen gene, but bare siRNA breaks down fast and crosses cell walls poorly.
The team loaded labeled siRNA into human exosomes from several sources by varied methods. Microscope and flow tests showed the vesicles handed the cargo to target cells. Two siRNAs aimed at DNA repair genes silenced their targets once delivered. One broke down its target protein and curbed cell growth as hoped. The study gives early proof that natural vesicles can ferry therapy RNA.
Catalog record
| CREATOR | Shtam TA, Kovalev RA, Varfolomeeva EY, Makarov EM, Kil YV, Filatov MV. |
|---|---|
| YEAR | 2013 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 41 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Exosomes are natural carriers of exogenous siRNA to human cells in vitro By Tatyana A Shtam, Roman A Kovalev, Elena Yu Varfolomeeva, Evgeny M Makarov, Yury V Kil, Michael V Filatov Published in: Cell Communication and Signaling : CCS DOI: 10.1186/1478-811X-11-88 ABSTRACT Background Exosomes are nano-sized vesicles of endocytic origin that are involved in cell-to-cell communication including shuttle RNA, mainly mRNA and microRNA. As exosomes naturally carry RNA between cells, these particles might be useful in gene cancer therapy to deliver therapeutic short interfering RNA (siRNA) to the target cells. Despite the promise of RNA interference (RNAi) for use in therapy, several technical obstacles must be overcome. Exogenous siRNA is prone to degradation, has a limited ability to cross cell membranes and may induce an immune response. Naturally occurring RNA carriers, such as exosomes, might provide an untapped source of effective delivery strategies. Results This study demonstrates that exosomes can deliver siRNA to recipient cells in vitro. The different strategies were used to introduce siRNAs into human exosomes of various origins. The delivery of fluorescently labeled siRNA via exosomes to cells was confirmed using confocal microscopy and flow cytometry. Two different siRNAs against RAD51 and RAD52 were used to transfect into the exosomes for therapeutic delivery into target cells. The exosome-delivered siRNAs were effective at causing post-transcriptional gene silencing in recipient cells. Moreover, the exosome-delivered siRNA against RAD51 was functional and caused the massive reproductive cell death of recipient cancer cells. Conclusions The results strongly suggest that exosomes effectively delivered the siRNA into the target cells. The therapeutic potential of exosome-mediated siRNA delivery was demonstrated in vitro by the strong knockdown of RAD51, a prospective therapeutic target for cancer cells. The results give an additional evidence of the ability to use human exosomes as vectors in cancer therapy, including RNAi-based gene therapy. BACKGROUND The use of small interfering RNAs to induce gene silencing has opened a new avenue in drug discovery. In the past decade, efforts to develop RNA-based therapeutic technologies have been significantly intensified [1-3]. Triggering RNA interference (RNAi), in particular, has become one of the most widely used techniques for biomedical applications [4-6]. RNAi uses a mechanism of posttranscriptional sequence specific gene silencing by processing double-stranded RNAs into small-interfering RNAs (siRNAs) used as part of the RNA-induced silencing complex to selectively cleave target mRNA [7]. After the discovery that synthetic siRNAs can be exogenously introduced into cells to activate RNAi [8], this approach has become a powerful method for selective suppression of specific genes of interest in different species, showing potential for use in cancer therapeutics [2,3]. However, the biomedical utility of the synthetic siRNAs is limited by several RNA structure-related factors such as the negative charge (uptake by cells that also have a negatively charged surface) and instability in the blood circulation (non-modified siRNAs have a very short half-life in the blood stream, mostly because of degradation by nucleases) [9]. Another major barrier is immunogenicity of the synthetic siRNAs or delivery vehicle, especially if repeated dosing is needed to treat disease [9,10]. These impediments can be overcome by using natural carriers of exogenous siRNA to human cells. Naturally occurring RNA carriers, such as exosomes, might provide an untapped source of effective delivery strategies [11]. Exosomes are nano-sized vesicles (30–120 nm in size) produced by many cell types, including dendritic cells (DC), B cells, T cells, mast cells, epithelial cells and tumor cells [12-15]. These vesicles are formed by inward budding of late endosomes and are then released to the extracellular environment upon fusion with the plasma membrane [15]. They have been detected in body fluids such as peripheral blood, urine, malignant effusions and bronchoalveolar lavage fluid [12,14,15]. It has been shown that these vesicles are involved in signal transduction, antigen presentation to T cells and tolerance development [12,15]. In 2007, it was demonstrated that exosomes derived from various cell types contain a substantial amount of RNA (mainly mRNA and microRNA) [16]. More importantly, the exosome vesicles shuttle RNA between cells, an activity which served as a novel means of cell-to-cell communication [12,17]. The RNA present in exosomes was therefore termed exosomal shuttle RNA (esRNA) [17]. As exosomes naturally carry RNA between cells, it has been speculated that this property might be useful in gene therapy, in which a vector is used to deliver therapeutic nucleic acids to the patient’s target cells [18-20]. In this report, we examined whether human exosomes can deliver exogenous nucleic acids to recipient cells in vitro. In 2008, we investigated survivability of human cells and their ability to pass through the cell cycle after suppressing the homologous recombination genes by gene-specific siRNAs [21]. We demonstrated that in most cancer cell types studied the decrease in the RAD51 protein level induced cell accumulation in S and G2 phases of the cell cycle and ultimately led to the massive reproductive cell death. Our data pointed to RAD51 as a potential target for repressing the growth of abnormally proliferating cells [21]. Here, we show that the exosome-delivered siRNA against RAD51 was also functional and caused the massive reproductive cell death of recipient cells. These findings suggest that exosomes derived from human cells can be utilized in gene cancer therapy to provide target cells with heterologous nucleic acids such as therapeutic siRNAs. RESULTS Introduction of siRNA into exosomes and delivery of heterologous siRNAs to recipient cells via exosomes Exosomes originating from HeLa and ascites were isolated by ultracentrifugation, as described earlier [22]. Size determination of isolated exosomes was performed using a Microtrac S3500 particle analyzer (Microtrac Inc) according to the manufacturer’s instructions (Figure 1A). The ultracentrifuge pellets of exosomes contained spherical particles that were in accordance with the exosome size range described earlier [12,15,22]. To estimate the homogeneity of the particles the atomic force microscopy method was used. The exosomes appeared as homogeneous circular bulging vesicular structures (Figure 1B). We also confirmed the presence of exosomal marker proteins HLA-ABC and CD63 [15] on the surface of these vesicles by dot blot analysis. [Figure: Characterization of exosomes originating from malighnant ascitic fluid. A, the sizes of all particles in the ultracentrifuge pellet were determined using a Microtrac S3500 particle analyzer. B, exosomes observed under atomic force microscopy (AFM), area scan is 5×5 micrometers.] Next, we investigated the possibility of loading exosomes with exogenous cargoes using chemical treatment. As chemical transfection for membrane particles at the nanometer scale is not well-characterized, nonspecific Alexa flour 488 labeled siRNA (siRNA AF488) was used for the empirical optimization of the protocol. To examine the efficiency of chemical loading of exosomes, siRNA AF488 was mixed with Lipofectamine to allow for the formation of complexes (siRNA embedded in lipid micelles), which was then added to the exosomes and incubated for 30 min at RT. The mixture was purified for 3-5 times by washing and ultra-filtration through a 100-kDa filter to eliminate the excess of free siRNA as well as siRNA embedded into the micelles (Exo + siRNA + LP + WF). Exosomes loaded with siRNA were co-cultured with the recipient cells for 24 h in order to transfect cells with the heterologous siRNA. High delivery efficiency of siRNA by exosomes to recipient cells was confirmed by confocal microscopy and flow cytometry (Figure 2A,B). The